Abstract
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are diverse immune systems found in many prokaryotic genomes that target invading foreign DNA such as bacteriophages and plasmids. There are multiple types of CRISPR with arguably the most enigmatic being Type IV. During an investigation of CRISPR carriage in clinical, multi-drug resistant, Klebsiella pneumoniae, a Type IV-A3 CRISPR-Cas system was detected on plasmids from two K. pneumoniae isolates from Egypt (isolated in 2002–2003) and a single K. pneumoniae isolate from the United Kingdom (isolated in 2017). Sequence analysis of all other genomes available in GenBank revealed that this CRISPR-Cas system was present on 28 other plasmids from various Enterobacteriaceae hosts and was never found on a bacterial chromosome. This system is exclusively located on IncHI1B/IncFIB plasmids and is associated with multiple putative transposable elements. Expression of the cas loci was confirmed in the available clinical isolates by RT-PCR. In all cases, the CRISPR-Cas system has a single CRISPR array (CRISPR1) upstream of the cas loci which has several, conserved, spacers which, amongst things, match regions within conjugal transfer genes of IncFIIK/IncFIB(K) plasmids. Our results reveal a Type IV-A3 CRISPR-Cas system exclusively located on IncHI1B/IncFIB plasmids in Enterobacteriaceae that is likely to be able to target IncFIIK/IncFIB(K) plasmids presumably facilitating intracellular, inter-plasmid competition.
Introduction
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR-Cas) are widespread, adaptive, RNA-mediated, immune systems found in the genomes of prokaryotic organisms (bacteria and archaea) that target invading foreign DNA such as bacteriophages and conjugative plasmids (; ). CRISPR functions through a three-stage process: adaptation involving the acquisition of foreign DNA molecules as spacers, expression and maturation of the short CRISPR RNAs (crRNAs), and the interference with a cognate invading foreign DNA molecule (). The classification of CRISPR-Cas systems is continuously updated to include newly identified subtypes. To date, CRISPR-Cas systems are classified into two classes, six Types (I–VI), and ∼ 33 subtypes (; , ). There is ongoing discovery of multiple, novel class 2 CRISPR-Cas systems (). The two classes differ according to the effector module; class 1 utilizes multi-protein effector Cas complexes, while class 2 utilizes a single-protein effector [Type II contains Cas9; Type V contains Cas 12a (previously known as Cpf1), Cas12b (previously known as C2c1), Cas12c (previously known as C2c3), Cas12d (previously known as CasY), and Cas12e (previously known as CasX); and Type VI contains Cas13a (previously known as C2c2), Cas13b, and Cas13c] (; , ; ). CRISPR-Cas systems are confirmed, or expected, to provide immunity against viruses and other mobile genetic elements (MGEs), except for transposon-encoded CRISPR-Cas systems that lack the interference module and therefore are predicted to perform functions distinct from adaptive immunity (). Most of the CRISPR types target DNA, some types specifically target RNA such as Type VI, while Type III CRISPR systems are unique because they exhibit both RNA interference and DNA interference in vivo to protect their microbial hosts (, ; ; ; ; ; ; ; ; ; ; ; ; ; ; ).
Type IV was previously called the Unknown Type (Type U), due to its rare occurrence and lack of the adaptation module, until an updated classification in 2015 (; ). It was then named Type IV (putative) after its identification in Acidithiobacillus ferrooxidans presenting a different genetic arrangement of Type U cas genes (). In 2017, Type IV classification was updated, after its identification in Thioalkalivibrio sp. K90mix (TK90_2699-TK90_2703), to show an associated repeat-spacer array for a cas loci that have csf4 (dinG), csf5 (cas6-Like), csf1 (cas8-Like), csf2 (cas7), and csf3 (cas5) genetic arrangement, respectively, and was then assigned as Type IV-A (). In 2018, a variant of Type IV that lacks a repeat-spacer array from Rhodococcus jostii RHA1 (RHA1_ro10069-RHA1_ro10072), was assigned as Type IV-B (Figure 1; ). In 2019, the Type IV-C CRISPR-Cas system was formally classified as a distinct subtype after its identification in nine contigs; mostly from thermophilic microorganisms (). Other papers have also proposed the classification of Type IV-D, Type IV-E, and subgroups of Type IV-A(1-4) (; ), however, the suggested subgroups did not have a unified genetic arrangement corresponding for each of the named Type IV-A(1-4) variants. Type IV CRISPR-Cas systems were shown to employ crRNA-guided effector complexes (). Type IV is the only type to possesses csf4 (dinG) in its CRISPR-Cas loci (; ), and it was recognized initially as the signature proteins for Type IV systems, (; ) although recently subtype IV-D has been shown to carry a helicase of the RecD family in place of the archetypal DinG (). To date, Type IV variants (IV-A, IV-B, and IV-C) described above show different genetic arrangements and orientation of cas loci, and they all lack the adaptation module. Also, all Type IV CRISPR-Cas systems are encoded by bacterial plasmids, prophages or other, uncharacterized integrated elements (). Thus, it has been hypothesized that Type IV is similar to an ancestral innate immune system that gained adaptive ability by associating with a transposon-like element containing cas1 and cas2 ().
FIGURE 1
Materials and Methods
Clinical Isolates Sequencing
Three clinical isolates were investigated; Klebsiella pneumoniae-53 and K. pneumoniae-65 were isolated from Egyptian university teaching hospitals (2002–2003), and K. pneumoniae-CR5 from University College London Hospital in the United Kingdom (2017). The bacterial genomic DNA sequencing was conducted at MicrobesNG (Birmingham, United Kingdom). Isolates were sequenced using an Illumina HiSeq 2500 and an Illumina MiSeq instruments, to boost coverage, with a 2 × 250 bp paired end sequencing using Nextera XT library prep.
CRISPR-Cas System Identification and Characterization
DNA sequences were analyzed using CRISPRFinder, CRISPRCasFinder, CRISPRTarget, and Snapgene (GSL Biotech) (
CRISPR-Cas System Expression
The CRISPR-Cas loci expression was tested. RT-PCR was performed using LightCycler® RNA Amplification Kit SYBR Green (Roche Diagnostics Ltd., United Kingdom). The primers were designed for fully characterized genes (csf2-fw:AAAATGCGGTCTCAACTTCCG; csf2-rev:TGACGAAGAG TTCCCCGAATG), (dinG-fw:GAGTCTGCCGGATTGTCGTTA; dinG-rev:GTACCAGATAGCCCAGCGTTT), and (cas6-fw:AAT GCGTTTCGGTTGCGTATC; cas6-rev:GAGTACGGCAGCTT CTCTCC).
Results and Discussion
Identification of Type IV-A3 CRISPR-Cas in Clinical and GenBank Isolate Sequences
Type IV-A-3 CRISPR-Cas, based on the gene composition and genetic architecture of the IV-A variants detected in K. pneumoniae as described in
This Type IV-A3 CRISPR-Cas is characterized by the presence of a cas loci containing dinG, which is a distinct feature of Type IV-A CRISPR-Cas system that was shown to be a requirement for the system functional activity in Pseudomonas aeruginosa (
Association Between Type IV-A3 CRISPR-Cas Sequences and IncHI1B/IncFIB(Mar) Plasmids
We also identified partial related Type IV-A3 systems either (cas8-like, cas6, and dinG) or (cas7 and a CRISPR array) occurring on other IncHI1B/IncFIB(Mar) plasmids (Supplementary Table S1). Partial and complete Type IV-A3 system characterization showed occurrence of a range of different IS elements and retrotransposons (group II introns) (Supplementary Table S1). The average GC content of this Type IV-A3 CRISPR-Cas loci (47.7 ± 0.01%) was found to be closer to that of the IncHI1B/IncFIB(Mar) plasmids on which they reside (46.2 ± 0.01%), compared to the chromosomal sequences of the bacterial host (57 ± 0.02%), (Table 1).
TABLE 1
| Sequence (strain name, plasmid name, Accession number) | Chromosomal Size (bp) | Chromosomal GC Content (%) | Plasmid Size (bp) | Plasmid GC Content (%) | New Type IV-A Size (bp) | New Type IV-A GC Content (%) | |
| 1 | K. pneumoniae 234-12, pKpn23412-362, CP011314.1 | 5,278,254 | 57 | 361,964 | 48 | 5,671 | 47 |
| 2 | K. pneumoniae Kp15, pENVA, HG918041.1 | * | * | 253,984 | 47 | 6,093 | 47 |
| 3 | E. coli strain Ecol_422, pEC422_1, CP018961.1 | 4,747,607 | 51 | 289,903 | 46 | 5,864 | 48 |
| 4 | K. pneumoniae 825795-1, unnamed1, CP017986.1 | 5,373,055 | 51 | 244,706 | 45 | 5,979 | 48 |
| 5 | K. pneumoniae KP_Goe_828304, pKp_Goe_304-1, CP018720.1 | 5,373,056 | 58 | 246,757 | 45 | 6,034 | 48 |
| 6 | K. pneumoniae Kp_Goe_152021, pKp_Goe_021-1, CP018714.1 | 5,373,055 | 58 | 246,756 | 45 | 5,979 | 48 |
| 7 | K. pneumoniae Kp_Goe_827026, pKp_Goe_026-1, CP018708.1 | 5,373,056 | 57 | 246,756 | 45 | 6,034 | 48 |
| 8 | K. pneumoniae Kp_Goe_827024, pKp_Goe_024-1, CP018702.1 | 5,374,118 | 57 | 246,753 | 45 | 6,034 | 48 |
| 9 | K. pneumoniae Kp_Goe_149832, pKp_Goe_832-1, CP018696.1 | 5,373,057 | 57 | 246,755 | 45 | 6,034 | 48 |
| 10 | K. pneumoniae MS6671.v1, LN824134.1 | 5,402,900 | 57 | 279,305 | 47 | 7,044 | 47 |
| 11 | K. pneumoniae, pNDM-MAR, JN420336.1 | * | * | 267,242 | 47 | 8,215 | 46 |
| 12 | K. pneumoniae A64477, pKP64477b, MF150122.1 | * | * | 205,089 | 45 | 6,282 | 47 |
| 13 | P. gergoviae FB2, pFB2.1, CP014776.1 | 5,489,680 | 59 | 242,312 | 45 | 5,921 | 48 |
| 14 | K. pneumoniae KPN528, pKPN528-1, CP020854.1 | 5,383,018 | 57 | 292,471 | 46 | 5,676 | 48 |
| 15 | K. pneumoniae Kp_Goe_149473, pKp_Goe_473-1, CP018687.1 | 5,373,056 | 57 | 246,757 | 45 | 5,979 | 48 |
| 16 | K. pneumoniae Kp_Goe_822579, pKp_Goe_579-1, CP018313.1 | 5,381,436 | 57 | 245,975 | 45 | 5,979 | 48 |
| 17 | K. pneumoniae Kp_Goe_154414, pKp_Goe_414-1, CP018339.1 | 5,159,815 | 58 | 204,862 | 45 | 5,738 | 48 |
| 18 | K. pneumoniae AR_0068, unitig_1, CP020068.1 | 5,357,430 | 57 | 276,460 | 47 | 5,678 | 48 |
| 19 | K. pneumoniae 11, pIncHI1B_DHQP1300920, CP016921.1 | 5,184,828 | 58 | 283,369 | 46 | 5,678 | 48 |
| 20 | K. pneumoniae KP617, KP-plasmid1, CP012754.1 | 5,416,282 | 57 | 273,628 | 46 | 5,678 | 48 |
| 21 | K. pneumoniae PittNDM01, plasmid1, CP006799.1 | 5,348,284 | 58 | 283,371 | 46 | 5,678 | 48 |
| 22 | K. pneumoniae SKGH01, unnamed 1, CP015501.1 | 5,490,611 | 57 | 281,190 | 47 | 7,036 | 49 |
| 23 | K. pneumoniae PMK1, pPMK1-NDM, CP008933.1 | 5,317,001 | 57 | 304,526 | 47 | 8,521 | 46 |
| 24 | K. pneumoniae KPNIH48, pKPN-edaa, CP026398.1 | 5,531,975 | 57 | 249,238 | 47 | 6,032 | 48 |
| 25 | K. pneumoniae KPN1481, pKPN1481-1, CP020848.1 | 5,554,150 | 58 | 347,748 | 47 | 8,518 | 48 |
| 26 | K. pneumoniae KSB2_1B, unnamed1, CP024507.1 | 5,228,889 | 58 | 310,025 | 47 | 5,678 | 48 |
| 27 | K. pneumoniae KPNIH50, pKPN-bbef, CP026172.1 | 5,616,605 | 57 | 243,967 | 46 | 6,042 | 48 |
| 28 | K. pneumoniae F44, p44-1, CP025462.1 | 5,460,465 | 57 | 261,706 | 48 | 5,434 | 48 |
| 29 | K. pneumoniae-53, plasmid1, SGOL01000000 | 6,501,177 | 59 | 45,187 | 46 | 5,671 | 47 |
| 30 | K. pneumoniae-65, plasmid 1, SGOK01000000 | 5,850,021 | 57 | 45,574 | 46 | 5,671 | 47 |
| 31 | K. pneumoniae-CR5, plasmid 1, SGOJ01000000 | 5,871,238 | 59 | 125,699 | 43 | 6,284 | 48 |
| A | K. pneumoniae K66-45, pK66-45-1, CP020902.1 | 5,380,605 | 57 | 338,512 | 48 | 6,078 | 46 |
| B | K. pneumoniae AR_0158, tig00000727, CP021699.1 | 5,165,071 | 58 | 354,705 | 48 | 3,177 | 48 |
| C | K. pneumoniae LS356, pKP8-2, CP025638.1 | 5,409,425 | 58 | 153,586 | 49 | 3,133 | 47 |
| D | K. oxytoca pKOX3, p1, KY913897.1 | * | * | 239,374 | 47 | 1,085 | 48 |
| Average | 5,422,844 | 57 | 251,035 | 46.2 | 5,875 | 47.7 | |
| STD | 286,043 | 0.0172 | 69,579 | 0.012 | 1,321 | 0.01 |
Comparison of the GC content of the CRISPR, host plasmid and host strain chromosome.
GC content comparison among the newly described Type IV-A CRISPR-Cas loci, the IncHI1B/IncFIB(Mar) plasmid and isolate chromosomal sequences of the host. *The strain chromosomal sequence was not available on GenBank; only the plasmid sequence was available.
Characterization of the Type IV-A3 CRISPR-Cas System Found in Enterobacteriaceae
A single CRISPR array (CRISPR1) was identified upstream of all cas loci. The repeats have a predicted stem-loop secondary-structure (Figures 2A,B) and is likely involved in a pre-crRNA Cas6-mediated process. The alignment of the regions around and containing the protospacer, particularly the last six positions preceding the protospacer, associated with CRISPR1 repeats revealed the conservation of the putative PAM signature (AAG) adjacent to the end of the protospacers (Figure 2C). A highly conserved 65 bp leader sequence occurring between the CRISPR-Cas loci and the CRISPR array was observed in all the sequences (Figure 2D). The minor variations in the leader sequence only occurred in two sequences (C in position −63 is A in CP014776.1 Pluralibacter gergoviae, and G in position −41 is A, and C in position −39 is T in K. pneumoniae-CR5 ST-392). The high conservation of the leader sequence is unlike that presented in
FIGURE 2

Type IV-A3 conserved repeats and the predicted stable stem-loop secondary structure, putative PAM and leader sequence. (A) Type IV-A-variant conserved repeats. The height of the letters in the sequence logo shows the relative frequency of their recurrence at that position. Wobbles at positions 16 and 17 are within the loop of the predicted stem-loop structure and are therefore tolerated in the structural prediction shown in (B). (B) The predicted secondary structure of direct repeats and the associated Minimum Free Energy (MFE) estimated in (kcal/mol) shown underneath the structure. This structure is predicted to be involved in the mechanism of pre-crRNA processing. (C) Type IV-A-variant conserved putative protospacer adjacent motifs (PAMs). The alignment of the regions containing protospacers shows the conservation of putative PAM signature (AAG), position –3 to –1, adjacent to the end of the protospacers, using WebLogo. The analysis was performed on all the detected (467 spacers) of the 31 CRISPR1 arrays analyzed, specifically, spacer matching 9% (42/467) to bacteriophages and 25.5% (119/467) to plasmid sequences. Searches for other subtypes/variants were unsuccessful, likely due to the low number of spacer–protospacer matches (D) Conserved Type IV-A-variant CRISPR leader. The WebLogo shows a highly conserved 65 bp occurring between the CRISPR-Cas loci an the CRISPR array among the sequences investigated in this study.
TABLE 2
| Isolate | Gene‡ | |||
| rpoB* | cas7/csf2 | dinG/csf4 | cas6/csf5 | |
| K. pneumoniae-CR5 | 16.71 | 22.385 | 23.865 | 23.69 |
| K. pneumoniae-CR5 RT-ve CTRL** | 31.21 | 37.48 | 42.52 | 34.755 |
| K. pneumoniae-53 | 16.595 | 24.2 | 25.305 | 25.325 |
| K. pneumoniae-53 RT-ve CTRL** | 32.65 | 37.74 | 34.37 | 33.61 |
| K. pneumoniae-65 | 17.575 | 23.2 | 24.745 | 24.44 |
| K. pneumoniae-65 RT-ve CTRL** | 32.23 | 42.79 | 46 | 34.045 |
RT-PCR data of the confirmed cas loci (cas7, dinG, and cas6) in the three clinical isolates.
†Genes amplification data represent the average of two experiments at least. The cut-off cycle threshold (Ct) was 30 cycles. *rpoB housekeeping gene was used as the internal positive control. **RT-ve CTRL represent no addition of the reverse transcriptase which was used as the negative control for residual DNA.
We have detected a total of 467 spacers in the 31 CRISPR1 arrays analyzed, out of which 9% (42/467) match to bacteriophages and 25.5% (119/467) match to plasmid sequences. The majority of spacer sequences are present in more than one spacer array and some are present more than once within the same array (Figure 3). Plasmid targeting spacers appeared in every example of this Type IV-A3 associated CRISPR array analyzed. Sequence analysis revealed that spacers correspond to IncFIIK conjugal transfer genes; traN and traL (Figure 3). Limited conservation within the order of the spacer arrays showed that the arrays cluster into two distinct groups which share geographical associations and suggest persistence within the plasmid pool in isolates from certain countries over time (Figure 4).
FIGURE 3

Newly described Type IV-A3 CRISPR spacer polymorphism. The spacers map. Only spacers are represented by boxes, and no repeats are included. Identical spacers are represented by the same number and color, while unique spacers are represented by white color and no number is associated with the box. Self-targeting spacers are indicated by letter (S) and show 100% identity to host DNA, plasmid-targeting spacers are indicated by letter (P), phage targeting spacers are indicated by letters (Ph), other Enterobacteriaceae targeting spacers (100% identity) are indicated by letter (O), cryptic spacers with similarity to other bacterial DNA are indicated by letters (CO), and those with similarity to Eukaryotic DNA are indicated by letters (CE) that are positioned underneath the relevant spacer. CE spacers showed at least 57% identity to eukaryotic DNA. CE spacers were confirmed by multiple sequences alignments. * KY913897.1 is the isolate that only has a CRISPR array and a cas7 (csf2) (not a complete Type IV system) and therefore is not included in the total analysis in Figure 4.
FIGURE 4

Evolutionary relationships of Type IV-A3 CRISPR spacer. The phylogenetic tree illustrating the evolutionary relationships of Type IV-A3 CRISPR array nucleotide sequences. Phylogenetic UPGMA tree was constructed using the MUSCLE algorithm of MEGA7. The evolutionary distances were computed using the Maximum Likelihood method and Tamura-Nei model, bootstrap test (1000 replicates), and the rate variation among sites was modeled with a gamma distribution (shape parameter = 2). The percentage of trees in which the associated taxa clustered together is shown next to the branches. The year and geographical origin of the isolate are listed to the right of the branch ends.
The CRISPR system described here is always found associated with IncH1B/IncFIB plasmids in Enterobacteriaceae, has dinG and cas7 (involved in interference), and cas6, cas5, and cas8-like (involved in expression and maturation of short crRNAs) (
Notably, some of the previously described Type IV systems do not possess a dinG or cas8-like (e.g., Type IV-C); however, cas7 genes are consistently found in all the previously and presently described Type IV sequences. Also, Cas7 is the most conserved protein among members of the Type IV CRISPR family (
This Type IV-A3 described here has a variable CRISPR array and a conserved leader sequence. The conserved leader sequence occurrence in a wide variety of K. pneumoniae sequence types may reflect their narrow association with IncH1B/IncFIB plasmids. Conserved leader sequences in other types (Type I-E) were shown to increase acquisition efficiency by presumably stabilizing the Cas1–2-leader-repeat interaction (
Type IV-A3 CRISPR system reported here is exclusively located on IncH1B/IncFIB plasmids. We have also spotted an imperfect spacer target in traN of an IncFIIK plasmid in K. pneumoniae-53 which suggests this plasmid may be able to evade plasmid mediated CRISPR interaction within this strain (
Type IV CRISPR-Cas systems demonstrate a notable diversity of molecular organization (Figure 1) and some appear to have taken on roles in addition to adaptive cellular immunity (
Statements
Author’s note
This manuscript has been released as a pre-print at BioRxiv (
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found at: https://www.ncbi.nlm.nih.gov/genbank/, SGOJ00000000; https://www.ncbi.nlm.nih.gov/genbank/, SGOK00000000; and https://www.ncbi.nlm.nih.gov/genbank/, SGOL00000000.
Author contributions
EN discovered the CRISPR system within the genomes of her Egyptian isolate collection, analyzed the sequence data, and wrote the first draft of the manuscript. SJ, AA, and VE designed and carried out the experiments to test cas loci expression. AR analyzed the data and wrote the manuscript. All authors critically reviewed and approved the manuscript.
Funding
EN was supported by a grant from the Schlumberger Foundation’s Faculty for the Future Program (2012–2016).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2020.01937/full#supplementary-material
References
1
AydinS.PersonneY.NewireE.LaverickR.RussellO.RobertsA. P.et al (2017). Presence of Type I-F CRISPR/Cas systems is associated with antimicrobial susceptibility in Escherichia coli.J. Antimicrob. Chemother.722213–2218. 10.1093/jac/dkx137
2
BarrangouR.FremauxC.DeveauH.RichardsM.BoyavalP.MoineauS.et al (2007). CRISPR provides acquired resistance against viruses in prokaryotes.Science3151709–1712. 10.1126/science.1138140
3
CarattoliA.ZankariE.Garcia-FernandezA.Voldby LarsenM.LundO.VillaL.et al (2014). In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing.Antimicrob Agents Chemother.583895–3903. 10.1128/aac.02412-14
4
CassS. D.HaasK. A.StollB.AlkhnbashiO. S.SharmaK.UrlaubH.et al (2015). The role of Cas8 in type I CRISPR interference.Biosci. Rep.35:e00197.
5
CouvinD.BernheimA.Toffano-NiocheC.TouchonM.MichalikJ.NeronB.et al (2018). CRISPRCasFinder, an update of CRISRFinder, includes a portable version, enhanced performance and integrates search for Cas proteins.Nucleic Acids Res.46W246–W251.
6
CrawleyA. B.HenriksenJ. R.BarrangouR. (2018). CRISPRdisco: an automated pipeline for the discovery and analysis of CRISPR-Cas systems.CRISPR J.1171–181. 10.1089/crispr.2017.0022
7
CrooksG. E.HonG.ChandoniaJ. M.BrennerS. E. (2004). WebLogo: a sequence logo generator.Genome Res.141188–1190. 10.1101/gr.849004
8
CrowleyV. M.CatchingA.TaylorH. N.BorgesA. L.MetcalfJ.Bondy-DenomyJ.et al (2019). A Type IV-A CRISPR-Cas system in Pseudomonas aeruginosa mediates RNA-guided plasmid interference In Vivo.CRISPR J.2434–440. 10.1089/crispr.2019.0048
9
DengL.GarrettR. A.ShahS. A.PengX.SheQ. (2013). A novel interference mechanism by a type IIIB CRISPR-Cmr module in Sulfolobus.Mol. Microbiol.871088–1099. 10.1111/mmi.12152
10
DwarakanathS.BrenzingerS.GleditzschD.PlagensA.KlinglA.ThormannK.et al (2015). Interference activity of a minimal Type I CRISPR-Cas system from Shewanella putrefaciens.Nucleic Acids Res.438913–8923. 10.1093/nar/gkv882
11
ElmoreJ. R.SheppardN. F.RamiaN.DeighanT.LiH.TernsR. M.et al (2016). Bipartite recognition of target RNAs activates DNA cleavage by the Type III-B CRISPR-Cas system.Genes Dev.30447–459. 10.1101/gad.272153.115
12
EstrellaM. A.KuoF. T.BaileyS. (2016). RNA-activated DNA cleavage by the Type III-B CRISPR-Cas effector complex.Genes Dev.30460–470. 10.1101/gad.273722.115
13
FaureG.MakarovaK. S.KooninE. V. (2019a). CRISPR-Cas: complex functional networks and multiple roles beyond adaptive immunity.J. Mol. Biol.4313–20. 10.1016/j.jmb.2018.08.030
14
FaureG.ShmakovS. A.YanW. X.ChengD. R.ScottD. A.PetersJ. E.et al (2019b). CRISPR-Cas in mobile genetic elements: counter-defence and beyond.Nature Rev. Microbiol.17513–525. 10.1038/s41579-019-0204-7
15
Garcillan-BarciaM. P.de la CruzF. (2008). Why is entry exclusion an essential feature of conjugative plasmids?Plasmid601–18. 10.1016/j.plasmid.2008.03.002
16
GoldbergG. W.JiangW.BikardD.MarraffiniL. A. (2014). Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting.Nature514633–637. 10.1038/nature13637
17
GrissaI.VergnaudG.PourcelC. (2007). CRISPRFinder: a web tool to identify clustered regularly interspaced short palindromic repeats.Nucleic Acids Res.35W52–W57.
18
GSL (2020). SnapGene Software. (Biotech Chicago, IL). (from GSL Biotech). Available online at: snapgene.com
19
HaleC. R.ZhaoP.OlsonS.DuffM. O.GraveleyB. R.WellsL.et al (2009). RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex.Cell139945–956. 10.1016/j.cell.2009.07.040
20
HofackerI. L. (2003). Vienna RNA secondary structure server.Nucleic Acids Res.313429–3431. 10.1093/nar/gkg599
21
JiangW.ManivI.ArainF.WangY.LevinB. R.MarraffiniL. A. (2013). Dealing with the evolutionary downside of CRISPR immunity: bacteria and beneficial plasmids.PLoS Genet.9:e1003844. 10.1371/journal.pgen.1003844
22
KamruzzamanM.IredellJ. R. (2019). CRISPR-cas system in antibiotic resistance plasmids in Klebsiella pneumoniae.Front. Microbiol.10:2934. 10.3389/fmicb.2019.02934
23
KazlauskieneM.TamulaitisG.KostiukG.VenclovasÈSiksnysV. (2016). Spatiotemporal control of Type III-A CRISPR-Cas immunity: coupling DNA degradation with the target RNA recognition.Mol. Cell62295–306. 10.1016/j.molcel.2016.03.024
24
KearseM.MoirR.WilsonA.Stones-HavasS.CheungM.SturrockS.et al (2012). Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data.Bioinformatics281647–1649. 10.1093/bioinformatics/bts199
25
KieperS. N.AlmendrosC.BrounsS. J. J. (2019). Conserved motifs in the CRISPR leader sequence control spacer acquisition levels in Type I-D CRISPR-Cas systems.FEMS Microbiol. Lett.366:fnz129.
26
KooninE. V.KrupovicM. (2015). Evolution of adaptive immunity from transposable elements combined with innate immune systems.Nat. Rev. Genet.16184–192. 10.1038/nrg3859
27
KooninE. V.MakarovaK. S. (2017). Mobile genetic elements and evolution of CRISPR-Cas systems: all the way there and back.Genome Biol. Evol.92812–2825. 10.1093/gbe/evx192
28
KooninE. V.MakarovaK. S.ZhangF. (2017). Diversity, classification and evolution of CRISPR-Cas systems.Curr. Opin. Microbiol.3767–78. 10.1016/j.mib.2017.05.008
29
KumarS.StecherG.TamuraK. (2016). MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets.Mol. Biol. Evol.331870–1874. 10.1093/molbev/msw054
30
LinJ.FengM.ZhangH.SheQ. (2020). Characterization of a novel type III CRISPR-Cas effector provides new insights into the allosteric activation and suppression of the Cas10 DNase.Cell Discov.6:29.
31
LundgrenM.CharpentierE.FineranP. C. (2015). CRISPR Methods and Protocols.New York, NY: Springer Science Business Media New York.
32
MakarovaK. S.KooninE. V. (2015). Annotation and classification of CRISPR-Cas systems.Methods Mol. Biol.131147–75. 10.1007/978-1-4939-2687-9_4
33
MakarovaK. S.WolfY. I.AlkhnbashiO. S.CostaF.ShahS. A.SaundersS. J.et al (2015). An updated evolutionary classification of CRISPR-Cas systems.Nature Rev. Microbiol.13722–736.
34
MakarovaK. S.WolfY. I.IranzoJ.ShmakovS. A.AlkhnbashiO. S.BrounsS. J. J.et al (2020). Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants.Nat. Rev. Microbiol.1867–83. 10.1038/s41579-019-0299-x
35
MakarovaK. S.WolfY. I.KooninE. V. (2013). The basic building blocks and evolution of CRISPR-CAS systems.Biochem. Soc. Trans.411392–1400. 10.1042/bst20130038
36
MakarovaK. S.WolfY. I.KooninE. V. (2018). Classification and nomenclature of CRISPR-Cas systems: where from here?CRISPR J.1325–336. 10.1089/crispr.2018.0033
37
MakarovaK. S.ZhangF.KooninE. V. (2017). SnapShot: class 1 CRISPR-Cas systems.Cell168946–946.e1. 10.1016/j.cell.2017.02.018
38
ManicaA.ZebecZ.SteinkellnerJ.SchleperC. (2013). Unexpectedly broad target recognition of the CRISPR-mediated virus defence system in the archaeon Sulfolobus solfataricus.Nucleic Acids Res.4110509–10517. 10.1093/nar/gkt767
39
MarraffiniL. A.SontheimerE. J. (2008). CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA.Science3221843–1845. 10.1126/science.1165771
40
MarraffiniL. A.SontheimerE. J. (2010a). CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea.Nature Rev. Genet.11181–190. 10.1038/nrg2749
41
MarraffiniL. A.SontheimerE. J. (2010b). Self versus non-self discrimination during CRISPR RNA-directed immunity.Nature463568–571. 10.1038/nature08703
42
MathewsD. H. (2005). Predicting a set of minimal free energy RNA secondary structures common to two sequences.Bioinformatics212246–2253. 10.1093/bioinformatics/bti349
43
MojicaF. J. M.Diez-VillasenorC.Garcia-MartinezJ.AlmendrosC. (2009). Short motif sequences determine the targets of the prokaryotic CRISPR defence system.Microbiology155(Pt 3)733–740. 10.1099/mic.0.023960-0
44
NewireE.AydinA.JumaS.EnneV. I.RobertsA. P. (2019). Identification of a Type IV CRISPR-Cas system located exclusively on IncHI1B/IncFIB plasmids in Enterobacteriaceae.bioRxiv [Preprint]. 10.1101/536375
45
OzcanA.PauschP.LindenA.WulfA.SchuhleK.HeiderJ.et al (2019). Type IV CRISPR RNA processing and effector complex formation in Aromatoleum aromaticum.Nat. Microbiol.489–96. 10.1038/s41564-018-0274-8
46
PengW.FengM.FengX.LiangY. X.SheQ. (2015). An archaeal CRISPR type III-B system exhibiting distinctive RNA targeting features and mediating dual RNA and DNA interference.Nucleic Acids Res.43406–417. 10.1093/nar/gku1302
47
Pinilla-RedondoR.Mayo-MuñozD.RusselJ.GarrettR. A.RandauL.SørensenS. J.et al (2019). Type IV CRISPR–Cas systems are highly diverse and involved in competition between plasmids.Nucleic Acids Res.482000–2012. 10.1093/nar/gkz1197
48
PyzochaN. K.ChenS. (2018). Diverse class 2 CRISPR-Cas effector proteins for genome engineering applications.ACS Chem. Biol.13347–356. 10.1021/acschembio.7b00800
49
RathD.AmlingerL.RathA.LundgrenM. (2015). The CRISPR-Cas immune system: biology, mechanisms and applications.Biochimie117119–128. 10.1016/j.biochi.2015.03.025
50
RavenhallM.SkuncaN.LassalleF.DessimozC. (2015). Inferring horizontal gene transfer.PLoS Comput. Biol.11:e1004095. 10.1371/journal.pcbi.1004095
51
SamaiP.PyensonN.JiangW.GoldbergG. W.Hatoum-AslanA.MarraffiniL. A. (2015). Co-transcriptional DNA and RNA cleavage during Type III CRISPR-Cas Immunity.Cell1611164–1174. 10.1016/j.cell.2015.04.027
52
ShenJ.LvL.WangX.XiuZ.ChenG. (2017). Comparative analysis of CRISPR-Cas systems in Klebsiella genomes.J. Basic Microbiol.57325–336.
53
SuzukiH.YanoH.BrownC. J.TopE. M. (2010). Predicting plasmid promiscuity based on genomic signature.J. Bacteriol.1926045–6055. 10.1128/jb.00277-10
54
TamulaitisG.KazlauskieneM.ManakovaE.VenclovasÈNwokeojiA. O.DickmanM. J.et al (2014). Programmable RNA shredding by the type III-A CRISPR-Cas system of Streptococcus thermophilus.Mol. Cell56506–517. 10.1016/j.molcel.2014.09.027
55
TaylorH. N.WarnerE. E.ArmbrustM. J.CrowleyV. M.OlsenK. J.JacksonR. N. (2019). Structural basis of Type IV CRISPR RNA biogenesis by a Cas6 endoribonuclease.RNA Biol.161438–1447. 10.1080/15476286.2019.1634965
56
ZebecZ.ManicaA.ZhangJ.WhiteM. F.SchleperC. (2014). CRISPR-mediated targeted mRNA degradation in the archaeon Sulfolobus solfataricus.Nucleic Acids Res.425280–5288. 10.1093/nar/gku161
57
ZhangQ.YeY. (2017). Not all predicted CRISPR-Cas systems are equal: isolated cas genes and classes of CRISPR like elements.BMC Bioinform.18:92. 10.1186/s12859-017-1512-4
58
ZhongZ.HelinskiD.ToukdarianA. (2005). Plasmid host-range: restrictions to F replication in Pseudomonas.Plasmid5448–56. 10.1016/j.plasmid.2004.11.001
59
ZimmermannL.StephensA.NamS. Z.RauD.KublerJ.LozajicM.et al (2018). A completely reimplemented MPI bioinformatics toolkit with a new HHpred server at its core.J. Mol. Biol.4302237–2243. 10.1016/j.jmb.2017.12.007
Summary
Keywords
Type IV, IncFIIK, IncFIB(K), inter-plasmid competition, mobile genetic element
Citation
Newire E, Aydin A, Juma S, Enne VI and Roberts AP (2020) Identification of a Type IV-A CRISPR-Cas System Located Exclusively on IncHI1B/IncFIB Plasmids in Enterobacteriaceae. Front. Microbiol. 11:1937. doi: 10.3389/fmicb.2020.01937
Received
04 May 2020
Accepted
22 July 2020
Published
12 August 2020
Volume
11 - 2020
Edited by
Kira Makarova, National Center for Biotechnology Information (NLM), United States
Reviewed by
Qunxin She, Shandong University, China; Samuel Henry Sternberg, Columbia University, United States
Updates

Check for updates
Copyright
© 2020 Newire, Aydin, Juma, Enne and Roberts.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Adam P. Roberts, adam.roberts@lstmed.ac.uk
†Present address: Enas Newire, Institute of Systems, Molecular & Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom Alp Aydin, Quadram Institute, Norwich, United Kingdom
This article was submitted to Evolutionary and Genomic Microbiology, a section of the journal Frontiers in Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.